Two Sigma Advisers LP Sells 109,231 Shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN)

Two Sigma Advisers LP trimmed its holdings in Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 24.6% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 335,569 shares of the company's stock after selling 109,231 shares during the period. Two Sigma Advisers LP owned about 0.42% of Viridian Therapeutics worth $6,433,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Voya Investment Management LLC lifted its holdings in shares of Viridian Therapeutics by 5.1% during the 4th quarter. Voya Investment Management LLC now owns 21,397 shares of the company's stock valued at $410,000 after purchasing an additional 1,038 shares in the last quarter. Tudor Investment Corp ET AL increased its position in shares of Viridian Therapeutics by 3.0% during the fourth quarter. Tudor Investment Corp ET AL now owns 38,367 shares of the company's stock worth $735,000 after acquiring an additional 1,106 shares in the last quarter. R Squared Ltd acquired a new stake in shares of Viridian Therapeutics during the fourth quarter worth $26,000. Summit Investment Advisors Inc. lifted its position in Viridian Therapeutics by 24.7% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after acquiring an additional 1,516 shares in the last quarter. Finally, AlphaQuest LLC lifted its position in Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock valued at $54,000 after acquiring an additional 1,519 shares in the last quarter.

Viridian Therapeutics Stock Performance

Shares of VRDN traded down $0.13 during mid-day trading on Friday, reaching $13.84. The company's stock had a trading volume of 88,876 shares, compared to its average volume of 1,187,029. The stock has a market cap of $1.13 billion, a P/E ratio of -3.21 and a beta of 0.57. The company has a current ratio of 18.55, a quick ratio of 18.55 and a debt-to-equity ratio of 0.04. The business has a 50-day simple moving average of $13.04 and a two-hundred day simple moving average of $16.55. Viridian Therapeutics, Inc. has a 1-year low of $9.90 and a 1-year high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last announced its earnings results on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping the consensus estimate of ($0.95) by $0.08. The company had revenue of $0.07 million for the quarter, compared to analysts' expectations of $0.16 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%. The firm's quarterly revenue was up .0% compared to the same quarter last year. As a group, equities research analysts anticipate that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have issued reports on VRDN. HC Wainwright reissued a "buy" rating and issued a $34.00 price target on shares of Viridian Therapeutics in a research note on Wednesday, April 23rd. The Goldman Sachs Group cut their target price on Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. JMP Securities decreased their price target on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating for the company in a research note on Wednesday, May 7th. Needham & Company LLC reiterated a "buy" rating and issued a $36.00 price objective on shares of Viridian Therapeutics in a report on Tuesday, May 20th. Finally, Royal Bank of Canada cut their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a research report on Wednesday, May 7th. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company's stock. According to data from MarketBeat.com, Viridian Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus price target of $36.70.

Viridian Therapeutics Company Profile

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.